Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022. Oncology Fact Sheet Nr. 81.

[thumbnail of Oncology Fact Sheet Nr.81_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
117kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 400-600 Ureter. Bladder. Urethra
Language:	English
Series Name:	Oncology Fact Sheet Nr. 81
Deposited on:	28 Mar 2022 12:38
Last Modified:	11 Jul 2022 13:38

Repository Staff Only: item control page